Loading
Merck & Co., Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 07 Feb 2025.
Merck & Co., Inc.: what insiders have been doing
Every trade that managers of Merck & Co., Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Rahway, United States. It was founded in 1891. In the past year (18 October 2025 to 18 October 2026), 85 filings came from 19 insiders.
There is no open-market purchase to report; the filings show 26 sales worth €39.1M by 9 insiders. One trade stands out by size: a sale of €9.3M from Zachary Jennifer, disclosed on 13 August 2026, or 0.0029% of market capitalisation.
Across the 5,813 companies tracked on its exchange, the median is 19 filings; at 85 filings, this issuer sits above that mark. The full history, which starts in 2021, counts 3 purchases against 43 sales. The 10-K for the year ended 31 December 2025 shows 65.01 bn USD of revenue and 18.25 bn USD of net income and a dividend of 3.28 USD per share.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
248
Thresholds
n/a
Buy Volume
€2M
3 ops. · all time
Sell Volume
€50M
43 ops. · all time
Who traded when
BuySaleRichard R. DeLuca9 sales
Chirfi Guindo5 sales
David Michael Williams5 sales
David R. Maraldo3 sales
Downing Cristal N2 sales
Oosthuizen Johannes Jacobus2 sales
+5 other insiders
Since the insiders bought
- +36.2%Entry US$86.40 · Close at T+365 US$117.65
- +36.2%Entry US$86.40 · Close at T+365 US$117.65
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Merck & Co., Inc. Buy (bullish), based on 25 analysts. Average price target: US$158.64.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 6,883 of 24,158 companies
62.3
score / 100
Value54
Quality71
FCF yld3.5%
Earn yld5.1%
EV/EBITDA14.4x
ROE7.0%
Gross mgn75%
Net mgn28%
Debt/EBITDA1.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$145.19
Analyst consensus
25 analystsBuy
US$105.00Target US$158.64(+9%)US$186.00
Income statement
RevenueUS$65B
Gross profitUS$48.6B75% margin
EBITDAUS$28.3B43% margin
Net incomeUS$18.3B4.8% margin
Valuation
PER (trailing)115.2x
PER (forward)15.6x
P/Book8.5x
Beta0.22
Balance sheet & cash
Market capUS$358.2B
Total debtUS$49.3B
Free Cash FlowUS$12.4B
Debt / Equity128%
Profitability & ownership
ROE7.0%
ROA11.9%
% insiders0.1%
% institutions83.0%
Last declaration on 13 August 2026
Declarations248 total
10,000 shares@ US$135.000.0004% mcap40.8% of flowCommonSEC144:0001950047-26-008057
10,000 shares@ US$135.000.0004% mcap5.6% of flowCommon StockSEC:0000310158-26-000223:0
80,315 shares@ US$133.45570.0029% mcap27.2% of flowCommon StockSEC:0000310158-26-000221:2
41,494 shares@ US$117.890.0013% mcap12.4% of flowCommon StockSEC:0000310158-26-000221:0
13,433 shares@ US$84.710.0003% mcap2.9% of flowCommon StockSEC:0000310158-26-000221:1
80,315 shares@ US$133.45570.0029% mcap100.0% of flowCommonSEC144:0001950047-26-008008
11,699 shares@ US$131.63450.0004% mcap22.9% of flowCommonSEC144:0001950047-26-008012
5,427 shares@ US$132.34960.0002% mcap2.1% of flowCommon StockSEC:0000310158-26-000219:2
11,099 shares@ US$131.61280.0004% mcap4.2% of flowCommon StockSEC:0000310158-26-000219:3
600 shares@ US$132.03670.0000% mcap0.2% of flowCommon StockSEC:0000310158-26-000219:4
20,784 shares@ US$130.43450.0007% mcap7.8% of flowCommon StockSEC:0000310158-26-000219:0
7,410 shares@ US$131.33130.0003% mcap2.8% of flowCommon StockSEC:0000310158-26-000219:1
12,837 shares@ US$131.76180.0005% mcap25.1% of flowCommonSEC144:0001950047-26-007942
20,784 shares@ US$130.43450.0007% mcap40.3% of flowCommonSEC144:0001950047-26-007905
805 shares@ US$131.02160.0000% mcap0.3% of flowCommon StockSEC:0000310158-26-000217:0
4,945 shares@ US$130.23120.0002% mcap1.9% of flowCommon StockSEC:0000310158-26-000217:1
300 shares@ US$131.02330.0000% mcap0.1% of flowCommon StockSEC:0000310158-26-000217:2
15,000 shares@ US$131.000.0005% mcap8.2% of flowCommon StockSEC:0000310158-26-000213:0
6,311 shares@ US$73.730.0001% mcap11.8% of flowCommon StockSEC:0000310158-26-000215:0
6,311 shares@ US$128.71790.0002% mcap20.6% of flowCommon StockSEC:0000310158-26-000215:1
9,709 shares@ US$87.100.0002% mcap21.4% of flowCommon StockSEC:0000310158-26-000215:2
9,709 shares@ US$128.71790.0003% mcap31.7% of flowCommon StockSEC:0000310158-26-000215:3
2,686 shares@ US$84.710.0001% mcap5.8% of flowCommon StockSEC:0000310158-26-000215:4
2,686 shares@ US$128.71790.0001% mcap8.8% of flowCommon StockSEC:0000310158-26-000215:5
4,600 shares@ US$128.77070.0002% mcap3.3% of flowCommon StockSEC:0000310158-26-000214:1
25 of 248 declarations
About Merck & Co., Inc.
Merck & Co., Inc. is a leading U.S. pharmaceutical company listed on the NYSE under the ticker MRK and headquartered in Rahway, New Jersey, in the United States. For French-speaking investors, Merck is best understood as a global healthcare platform rather than a single-product story: it operates across prescription medicines, vaccines, biologic therapies, and Animal Health. Outside the United States and Canada, the company uses the MSD brand. Merck reported approximately 75,000 employees and $65.0 billion in 2025 revenue, underscoring its scale as one of the major defensive large-cap names in global healthcare. ([merck.com](https://www.merck.com/media/company-fact-sheet/))
Founded in 1891, Merck has built a long-standing position in global pharmaceuticals through a combination of scientific depth, commercial execution, and sustained R&D investment. Its operating structure is centered on three main businesses: Pharmaceuticals, Vaccines, and Animal Health. The company’s research and development spend reached $15.8 billion in 2025, which reflects the capital intensity of maintaining a pipeline in oncology, infectious diseases, cardiometabolic care, and other therapeutic areas. ([merck.com](https://www.merck.com/media/company-fact-sheet/))
Read moreShow less
From a competitive standpoint, Merck is particularly strong in oncology and infectious disease prevention, while also holding a meaningful position in animal health. Its best-known franchise remains KEYTRUDA, the immuno-oncology cornerstone that continues to anchor the company’s earnings power. The company has also highlighted the launch momentum of WINREVAIR and the resilience of its Animal Health business as important contributors to 2024 growth. This mix gives Merck both earnings quality and pipeline optionality, although future performance remains highly dependent on patent cycles, clinical success, and launch execution. ([merck.com](https://www.merck.com/stories/our-q4-and-full-year-2024-financial-results/))
Merck’s geographic footprint is broad and diversified. In 2025, the United States generated $36.5 billion of revenue, followed by Europe, the Middle East and Africa at $14.6 billion, Latin America at $3.4 billion, Asia Pacific ex-Japan/China at $3.0 billion, Japan at $2.7 billion, China at $1.9 billion, and Other at $2.9 billion. That distribution shows a company with strong domestic exposure but also meaningful international monetization. ([merck.com](https://www.merck.com/media/company-fact-sheet/))
Recent developments have reinforced the investment case around innovation-led growth. In June 2025, the FDA approved ENFLONSIA, Merck’s RSV preventive monoclonal antibody for newborns and infants entering their first RSV season, adding a new respiratory asset to the portfolio. The company also reported positive Phase 3 data for enlicitide decanoate, an oral PCSK9 inhibitor in hyperlipidemia, and announced an agreement to acquire Cidara Therapeutics for about $9.2 billion to diversify further into late-phase antiviral assets. Taken together, these moves suggest Merck is actively refreshing its growth pipeline while defending its core franchises on the NYSE in the United States. ([merck.com](https://www.merck.com/news/u-s-fda-approves-mercks-enflonsia-clesrovimab-cfor-for-prevention-of-respiratory-syncytial-virus-rsv-lower-respiratory-tract-disease-in-infants-born-during-or-entering-their-fir/))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
